GSK plans to spin off Consumer Healthcare unit
GlaxoSmithKline (GSK) has plans to spin off its Consumer Healthcare unit by demerging a minimum of 80% of the company’s 68% stake to its shareholders.
GlaxoSmithKline (GSK) has plans to spin off its Consumer Healthcare unit by demerging a minimum of 80% of the company’s 68% stake to its shareholders.
US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m.
Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.
The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.
The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.
Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.
Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.
The US Food and Drug Administration (FDA) has approved Libtayo to be used for the treatment of patients having two of the most common skin cancers in the US.
Mylan and Pfizer announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.